Sunday, December 18, 2011
nanobots: Azacycles company introduces intelligent nanobots ...: PRAGUE (July 18th, 2011): The first generation of an intelligent nanocarriers, so called nanobots has been introduced by Azacycles (Kladn...
nanobots: New generation of nanobots has been introduced by ...: PRAGUE (November 14th, 2010): The Azacycles company (Kladno, Czech Republic) introduced first generation of highly effective nanocarriers l...
PRAGUE (December 18th, 2011): Azacycles introduced realized model of the Virus Trap technology concept. It represents quite new approach for designing of antiviral agents or antiviral drugs. The Virus Trap technology is unique for its entire independecy on surface epitopes of viruses therefore objectives of this technology will be RNA viruses as well as DNA viruses of all classes. The concept should be help in human medicine to solve such difficult questions as rare Ebola virus disease (EVD) or Marburg virus disease (MVD) as well as in warfare with HIV. By information of Simon Cihelnik (CEO), in next three years Azacycles is going to change the concept and such modified technology apply in area of bacterial diseases' therapy. The technology is based on Azacycles Nanobot technology 1nd generation outgoings. Mr. Cihelnik says: "Our nanobot technology in its first generation is able to provide excellent matrix of the antiviral, but only second generation, which is in state of its building, will allow to build antiviral nanobot in whole wide of our company's aim".
Friday, December 16, 2011
After almost nine months, the founding organization of the consortium Nanobot Research Group (NRG) decided to increase the expected level of mutual cooperation. On 15 December 2011 was signed a consortium agreement, a new consortium called Nanobot Special Interest Group (Nanobot SIG). The newly established consortium presented a certificate of membership, decision-making mechanisms and the composition of the consortium board, in broad outline the conditions of membership in the consortium. The consortium board immediately announced two candidates for membership in Nanobot SIG.
The main mission of the Nanobot Special Interest Group is a research and development of potentially effective therapeutically active nanobots and an increasing the flow of such early stage drug candidates into Nanobot SIG member's drug development pipeline in. Through the Nanobot SIG and the interactions among Nanobot SIG's participants, the Nanobot SIG drug discovery and development pipeline can be enabled from target identification through proof-of-concept (POC) to overall clinical trials. Because membership in the Nanobot SIG is fully open, to each the SIG's member is allowed to use all benefits of the SIG consortium agreement, at the most in intellectual property rights and in an access into confidential SIG's documents, methodics, technologies, strategic plans. In practical this means sharing of the technological know-how and intellectual property among all in-Nanobot-SIG interested parties, but only to the extent that corresponds to the input of each party to the consortium. It is at the discretion of each Nanobot SIG's member, how will share any intellectual property acquired during membership. In this respect, the consortium offers unprecedented Freedom-to-Operate.
The Consortium Board's Chairman Dr. Cihelnik said to question about new membership: "For all the founding members of the consortium that increase the level of cooperation is great promise, but also a commitment. As a representative of the company Azacycles I see this commitment as both a great opportunity for our company because our membership in the consortium will significantly increase the application range of our nanobots. We expect that over 6 years our nanobots will be a fundamental matrix of at least ten new types of targeted drugs of third parties in stages from proof-of-concept to first stage of clinical trials. Obviously, this challenge is a for our company so far essential that we also reconsider our relatively strict approach to opening up intellectual property to third parties. Of course, for the third parties such situations is very beneficial, since acquire a comprehensive package of technological solutions, which modify only by its superstructure. But strongly I note that the first deliveries are contracted on half of 2015. From technical reasons previously is not possible, we can not realistically consider the supply. This time we would like to use for further optimization of the nanobots' skeleton and the skeleton nanobots affix well by other sophisticated features."
"The new member must be beneficial for the consortium. This is the only rule. The consortium is obtaining from partly shared intellectual property and therefore the technology is able to provide is a crucial factor when deciding on a new member."
The primary nanobot technology is also opened for the members?
"No, of course it is not. Only Therapharm company is the Nanobot SIG founding member with ability to consult questions of our technology. Another founding members as well as general members are using the technology as black-box. It means that they are able to modify skeleton by our methodics through Nanobot SIG, but they are not able to do any changes in nanobot skeletons."
You have mentioned the skeleton modifications. What about this intellectual property?
"This is more complicated. Basically, there are two levels in the membership and only the founding members are holders of conjugation methodics. The idea, the basic concept of the Nanobot SIG is that the consortium will afford to third party, next general member, the complete kit from the nanobotic particles of the best parameters for third party application and from technology for modification of nanobot skeleton. In the most cases we are avaiting requests for modification by some specifically binding peptides. This is the role of our another founding members to make the best conjugation technologies generally applicable and also applicable for their own peptides. Third party as geenral member take this macroconjugate and modify it inside by its own biologically active compound. Because third party will have not to do any time consuming research, we expect shortening whole time from start of the design into clinical trials. Such approach is, by our opinion, unique."